Mylan to buy injectable drugs unit of Strides for $1.6 billion

Thu Feb 28, 2013 4:50am IST

Related Topics

Stocks

   

REUTERS - Generic drugmaker Mylan Inc (MYL.O) said it would buy the injectable drugs unit of Strides Arcolab Ltd (STAR.NS) for $1.6 billion to expand its presence in the fast-growing generic injectables market.

The deal for Agila Specialities, a wholly-owned subsidiary of Strides, caps months of uncertainty regarding its sale, with reports suggesting Pfizer Inc (PFE.N) and Japan's Otsuka Holdings Co Ltd as other potential buyers.

The deal will help Mylan, one of the world's largest generic drugmakers, double its injectable drugs portfolio.

A raft of patent expiries that will stretch until 2016 is expected to drive growth in the global generic injectables market. Also, many generic injectable drugs, which tend to be administered in hospitals, have been in short supply in the United States, including treatments for cancer.

"Together we will have more than 700 marketed injectables products and a global pipeline of more than 350 injectables products pending approval," Mylan President Rajiv Malik said.

Mylan said the acquisition of Bangalore-based Agila is expected to immediately add to its adjusted diluted earnings per share following closing.

"We expect the transaction to have a greater than 10 percent return on invested capital by the third full year from closing," CFO John Sheehan said in a conference call.

Mylan will also pay Strides Arcolab $250 million in potential milestone payments, it said.

Mylan said it will not assume any outstanding debt for the deal, which was unanimously approved by its board.

Separately, Mylan reported a 25 percent rise in fourth-quarter results profit, helped by sales of its Epipen auto-injector for the treatment of severe allergic reactions.

Mylan's shares were up 2 percent in extended trading after closing at $28.57 on Wednesday on the Nasdaq.

(Reporting By Adithya Venkatesan and Vrinda Manocha in Bangalore; Editing by Saumyadeb Chakrabarty)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Culling Plans

REUTERS SHOWCASE

Drug Approval

Drug Approval

Epirus, Ranbaxy win India approval for arthritis drug copy.  Full Article 

Fresh Demand

Fresh Demand

As mining curbs bite, India offers market to glut-hit iron ore.  Full Article 

Root Out 'Bad Apples'

Root Out 'Bad Apples'

RBI chief calls for cleaning up of banking system.  Full Article 

Android One

Android One

Google launches $105 Android One; eyes low-price smartphone boom.  Full Article 

Cognizant Deal

Cognizant Deal

Cognizant to buy TriZetto for $2.7 billion to boost healthcare business  Full Article 

India-Vietnam Ties

India-Vietnam Ties

India tightens Vietnam defence, oil ties ahead of China Xi's visit.  Full Article 

Antitrust Crusade

Antitrust Crusade

INSIGHT - "Mr. Confession" and his boss drive China's antitrust crusade .  Full Article 

Inflation Eases

Inflation Eases

Aug WPI inflation eases to near five-year low of 3.74 percent  Full Article 

Kashmir Floods

Kashmir Floods

Disease threatens as Kashmir flood waters turn fetid  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage